Solid Biosciences (SLDB) EBIT (2017 - 2026)

Solid Biosciences (SLDB) has 10 years of EBIT data on file, last reported at -$57.3 million in Q1 2026.

• For the quarter ending Q1 2026, EBIT fell 43.08% year-over-year to -$57.3 million; the trailing twelve-month figure through Mar 2026 stood at -$196.5 million (down 37.46% YoY), and the FY2025 full-year result was -$179.2 million, down 38.14% from the prior year.
• EBIT slipped to -$57.3 million in Q1 2026, from -$49.4 million in the prior quarter.
• In the past five years, EBIT ranged from a high of -$21.1 million in Q3 2022 to a low of -$57.3 million in Q1 2026.
• A 5-year average of -$33.9 million and a median of -$32.0 million in 2023 frame the typical range for EBIT.
• Across the five-year window, EBIT plunged 85.32% in 2022 and jumped 35.59% in 2023, its largest moves.
• Tracing SLDB's EBIT over 5 years: stood at -$34.6 million in 2022, then jumped by 35.59% to -$22.3 million in 2023, then sank by 79.19% to -$39.9 million in 2024, then declined by 23.83% to -$49.4 million in 2025, then declined by 16.0% to -$57.3 million in 2026.
• Business Quant data shows SLDB's EBIT at -$57.3 million in Q1 2026, -$49.4 million in Q4 2025, and -$48.1 million in Q3 2025.